Delivery Order SPE2DR25D1053-SPE2DR26FV907
Award Date 1/29/26
Potential Completion Date 1/30/26
Potential Value $14K
Federal Agency
Awardee
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $4,621.42 delivery order to AmerisourceBergen Drug Corp on January 28, 2026, for the supply of Actemra 162 mg/0.9 mL syringes. This is a firm fixed-price, non-set-aside contract with a completion date of January 29, 2026, and represents a child order under AmerisourceBergen's parent company, Cencora, Inc. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, where the contractor maintains its corporate office. This delivery order falls under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Actemra 400 mg/20 mL vials. This competitively awarded, firm fixed-price delivery order has a ceiling value of $7,109.81 and an ultimate completion date of July 30, 2025. The contract involves no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Actemra (tocilizumab) is a biologic immunosuppressant...
- The Defense Logistics Agency awarded a delivery order valued at $8,134.43 to AmerisourceBergen Drug Corp for the supply of ACTEMRA 162 mg/0.9 mL syringes on November 7, 2025, with an ultimate completion date of November 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's facility in Conshohocken, Pennsylvania. ACTEMRA (tocilizumab) is a biologic immunosuppressant medication commonly used to treat...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $22,888.50 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes on December 17, 2025, with an ultimate completion date of December 18, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Actemra (tocilizumab) is a biologic immunosuppressant medication used...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Actemra 400 mg/20 mL vials with a ceiling value of $4,191.38. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for completion by November 18, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This delivery order is a child contract under...
- On January 14, 2026, the Defense Logistics Agency (DLA) awarded a delivery order valued at $3,003.48 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 mL auto-injectors. This firm fixed-price delivery order is scheduled for completion by January 15, 2026, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The award was made on a competitive, non-set-aside basis and represents a task order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. The contract reflects a firm fixed price arrangement with an ultimate completion date of August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded without set-aside designation, consistent with the vendor's track...
- On January 2, 2026, the Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes valued at $12,275.06, with an ultimate completion date of January 5, 2026. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $7,194.60 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes on August 4, 2025, with an ultimate completion date of August 5, 2025. This firm fixed price delivery order, which was competitively awarded without set-aside designation, will be performed at the company's corporate headquarters in Conshohocken, Pennsylvania. Actemra is a biologic immunosuppressant medication commonly used in the treatment...
- This delivery order, awarded January 26, 2026, to AmerisourceBergen Drug Corp (a subsidiary of Cencora, Inc.) by the Defense Logistics Agency, provides for the supply of Actemra 162 mg/0.9 mL syringes valued at $14,463.51, with completion targeted for January 27, 2026. The award utilizes a firm fixed-price structure with no set-aside designation, indicating competitive selection. The contract will be performed at the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen...